Welcome to Celon Pharma S.A.

Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.

News

• Current report No. 26/2022 – Conclusion of the agreement on joint development and commercialization of an inhalation drug containing fluticasone and salmeterol in the US2 December 2022
  Current report No. 26/2022 Date prepared: 29/11/2022 Abbreviated name of the issuer: CELON PHARMA S.A. Topic     Conclusion of the agreement on joint development and commercialization of an inhalation drug containingRead more »
• Current report No. 25/2022 – Celon Pharma S.A.’s project on a new therapeutic objective for the FGF1 protein analogue will receive co-funding1 December 2022
  Current report No. 25/2022 Date prepared: November 21, 2022, time: 03:54 PM Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Celon Pharma S.A.’s project on a new therapeutic objectiveRead more »
• Current report No. 24/2022 – Celon Pharma S.A.’s project on improving drug safety by implementing innovative forms of orally administered medicinal products to the Company’s in-house production will receive co-funding1 December 2022
  Date prepared: 11/08/2022Legal basis: Article 17 (1) of the Market Abuse Regulation (MAR) – inside information, time: 07:45 PM Content of the report: The Management Board of Celon Pharma S.A.Read more »

Research and development

We create innovative drugs, that will change the lives of patients globally

Pipeline

Products

We are leaders in
inhalation technology

medicines